Brian A. Menegaz

Brian A. Menegaz

Auto-generated profile, based on publicly available information

Brian A. Menegaz

Department of Surgery, Breast surgical Oncology, Baylor College of Medicine, Houston, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in Nature
Verified
Journal Article
Closed access
PDF file
TKTapsi Kumar
Tapsi Kumar
KNKevin Nee
Kevin Nee
RWRunmin Wei
Runmin Wei
SHSiyuan He
Siyuan He
QNQuy H. Nguyen
Quy H. Nguyen
NNNicholas Navin
Nicholas Navin

16 April 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
EFEliza Li Shan Fong
Eliza Li Shan Fong
SLSalah-Eddine Lamhamedi-Cherradi
Salah-Eddine Lamhamedi-Cherradi
EBEmily Burdett
Emily Burdett
VRVandhana Ramamoorthy
Vandhana Ramamoorthy
ALAlexander J. Lazar
Alexander J. Lazar
JLJoseph Ludwig
Joseph Ludwig
The pronounced biological influence of the tumor microenvironment on cancer progression and metastasis has gained increased recognition over the past decade, yet most preclinical antineoplastic drug testing is still reliant on conventional 2D cell culture systems. Although monolayer cultures recapitulate some of the phenotypic traits observed clinically, they are limited in their ability to model the full range of microenvironmental cues, such as ones elicited by 3D cell–cell and cell–extracellular matrix interactions. To address these shortcomings, we established an ex vivo 3D Ewing sarcoma model that closely mimics the morphology, growth kinetics, and protein expression profile of human tumors. We observed that Ewing sarcoma cells cultured in porous 3D electrospun poly(ε-caprolactone) scaffolds not only were more resistant to traditional cytotoxic drugs than were cells in 2D monolayer culture but also exhibited remarkable differences in the expression pattern of the insulin-like growth factor-1 receptor/mammalian target of rapamycin pathway. This 3D model of the bone microenvironment may have broad applicability for mechanistic studies of bone sarcomas and exhibits the potential to augment preclinical evaluation of antineoplastic drug candidates for these malignancies.

9 June 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ELEsther H. Lips
Esther H. Lips
TKTapsi Kumar
Tapsi Kumar
AMAnargyros Megalios
Anargyros Megalios
LVLindy L. Visser
Lindy L. Visser
MSMichael Sheinman
Michael Sheinman
ESElinor J. Sawyer
Elinor J. Sawyer
Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and, despite treatment, a small fraction (5–10%) of DCIS patients develop subsequent invasive disease. A fundamental biologic question is whether the invasive disease arises from tumor cells in the initial DCIS or represents new unrelated disease. To address this question, we performed genomic analyses on the initial DCIS lesion and paired invasive recurrent tumors in 95 patients together with single-cell DNA sequencing in a subset of cases. Our data show that in 75% of cases the invasive recurrence was clonally related to the initial DCIS, suggesting that tumor cells were not eliminated during the initial treatment. Surprisingly, however, 18% were clonally unrelated to the DCIS, representing new independent lineages and 7% of cases were ambiguous. This knowledge is essential for accurate risk evaluation of DCIS, treatment de-escalation strategies and the identification of predictive biomarkers.

3 August 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MSMarco Santoro
Marco Santoro
SLSalah-Eddine Lamhamedi-Cherradi
Salah-Eddine Lamhamedi-Cherradi
BMBrian A. Menegaz
Brian A. Menegaz
JLJoseph Ludwig
Joseph Ludwig
AMAntonios G. Mikos
Antonios G. Mikos
Significance: Most preclinical drug screening systems fail to predict whether a given drug candidate will succeed in clinical trials due to the fact that cells are plated on culture dishes devoid of signaling cues present in vivo. Among other factors, biomechanical stimulation strongly affects tumor behavior. Toward this end, we cultured Ewing sarcoma cells on 3D scaffolds within a flow perfusion bioreactor, which provides mechanical stimulation in the form of flow-derived shear stress. Cells exposed to flow perfusion produced more insulin-like growth factor-1 (IGF-1) ligand and showed shear stress-dependent sensitivity to IGF-1 receptor targeted drugs when compared with static conditions. Collectively, this research provides an improved method to study cancer cells ex vivo and could narrow the gap between preclinical and clinical drug activity.

30 August 2016 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
SLSalah-Eddine Lamhamedi-Cherradi
Salah-Eddine Lamhamedi-Cherradi
BMBrian A. Menegaz
Brian A. Menegaz
VRVandhana Ramamoorthy
Vandhana Ramamoorthy
DVDeeksha Vishwamitra
Deeksha Vishwamitra
YWYing Wang
Ying Wang
JLJoseph Ludwig
Joseph Ludwig
Background: Therapies cotargeting insulin-like growth factor receptor 1 (IGF-1R) and mammalian target of rapamycin (mTOR) have demonstrated remarkable, albeit short-lived, clinical responses in a subset of Ewing sarcoma (ES) patients. However, the mechanisms of resistance and applicable strategies for overcoming drug resistance to the IGF-1R/mTOR blockade are still undefined. Methods: To elucidate predominant mechanism(s) of acquired drug resistance while identifying synergistic drug combinations that improve clinical efficacy, we generated more than 18 ES cell lines resistant to IGF-1R- or mTOR-targeted therapy. Two small-molecule inhibitors of IGF-1R were chosen, NVP-ADW-742 (IGF-1R-selective) and OSI-906 (a dual IGF-1R/insulin receptor alpha [IR-α] inhibitor). Reverse-phase protein lysate arrays (RPPAs) revealed proteomic changes linked to IGF-1R/mTOR resistance, and selected proteins were validated in cell-based assays, xenografts, and within human clinical samples. All statistical tests were two-sided. Results: Novel mechanisms of resistance (MOR) emerged after dalotuzumab-, NVP-ADW-742-, and OSI-906-based targeting of IGF-1R. MOR to dalotuzumab included upregulation of IRS1, PI3K, and STAT3, as well as p38 MAPK, which was also induced by OSI-906. pEIF4E(Ser209), a key regulator of Cap-dependent translation, was induced in ridaforolimus-resistant ES cell lines. Unique drug combinations targeting IGF-1R and PI3K-alpha or Mnk and mTOR were synergistic in vivo and vitro (P < .001) as assessed respectively by Mantel-Cox and isobologram testing. Conclusions: We discovered new druggable targets expressed by chemoresistant ES cells, xenografts, and relapsed human tumors. Joint suppression of these newfound targets, in concert with IGF-1R or mTOR blockade, should improve clinical outcomes.

1 December 2014 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
SLSalah-Eddine Lamhamedi-Cherradi
Salah-Eddine Lamhamedi-Cherradi
MSMarco Santoro
Marco Santoro
VRVandhana Ramammoorthy
Vandhana Ramammoorthy
BMBrian A. Menegaz
Brian A. Menegaz
GBGeoffrey Bartholomeusz
Geoffrey Bartholomeusz
JLJoseph Ludwig
Joseph Ludwig
Despite longstanding reliance upon monolayer culture for studying cancer cells, and numerous advantages from both a practical and experimental standpoint, a growing body of evidence suggests that more complex three-dimensional (3D) models are necessary to properly mimic many of the critical hallmarks associated with the oncogenesis, maintenance and spread of Ewing's sarcoma (ES), the second most common pediatric bone tumor. And as clinicians increasingly turn to biologically-targeted therapies that exert their effects not only on the tumor cells themselves, but also on the surrounding extracellular matrix, it is especially important that preclinical models evolve in parallel to reliably measure antineoplastic effects and possible mechanisms of de novo and acquired drug resistance. Herein, we highlight a number of innovative methods used to fabricate biomimetic ES tumors, encompassing both the surrounding cellular milieu and the extracellular matrix (ECM), and suggest potential applications to advance our understanding of ES biology, preclinical drug testing, and personalized medicine.